Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …

Proteomic studies for Alzheimer's disease (AD) are instrumental in identifying AD pathways
but often focus on single tissues and sporadic AD cases. Here, we present a proteomic study …

Alzheimer's disease (AD) pathology develops many years before the onset of cognitive
symptoms. Two pathological processes—aggregation of the amyloid-β (Aβ) peptide into …

Alzheimer's disease (AD) is the most common cause of dementia and is characterized by
aggregation of amyloid and tau proteins in the brain. Results from genetic studies suggest …

Objective Previous gene expression analysis identified a network of coexpressed genes that
is associated with β‐amyloid neuropathology and cognitive decline in older adults. The …

Background The complicated cellular and biochemical changes that occur in brain during
Alzheimer's disease are poorly understood. In a previous study we used an unbiased label …

A diverse set of biological processes have been implicated in the pathophysiology of
Alzheimer's disease (AD) and related dementias. However, there is limited understanding of …

Mass spectrometry-based proteomics empowers deep profiling of proteome and protein
posttranslational modifications (PTMs) in Alzheimer's disease (AD). Here we review the …

Alzheimer's disease (AD) is a neurodegenerative disease with heterogenous
pathophysiological changes that develop years before the onset of clinical symptoms. These …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that slowly destroys
memory and thinking skills, resulting in behavioral changes. It is estimated that nearly 36 …